UroGen Pharma to Present at Upcoming Investor Conferences

UroGen Pharma (Nasdaq: URGN), a biotech company focused on urothelial and specialty cancers, has announced its participation in two upcoming investor conferences.

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

08/29/2024 - 08:00 AM EDT

- H.C. Wainwright 26^th Annual Global Investment Conference -

- 2024 Cantor Global Healthcare Conference -

PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in fireside chats at the following investor conferences in September:

H.C. Wainwright 26^th Annual Global Investment Conference – September 9-11^th, 2024
Fireside Chat: September 9^th, 2024 at 9:00am ET
Location: New York, NY
Webcast Registration Link: Here

2024 Cantor Global Healthcare Conference – September 17-19^th, 2024
Fireside Chat: September 18, 2024 at 3:40pm ET
Location: New York, NY
Webcast Registration Link: Here

A webcast from the conference will also be available via the Investors section of UroGen’s website, www.urogen.com. A replay of the webcast will be available for approximately 90 days.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel^® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat low-grade upper tract urothelial cancer and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with LG-IR-NMIBC are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.UroGen.com to learn more or follow us on X (Twitter), @UroGenPharma.